Research Paper Volume 16, Issue 6 pp 5452—5470

Cyclocarya paliurus leaves alleviate high-sucrose diet-induced obesity by improving intestinal metabolic disorders

Ye Yao1, , Xiaojuan Wang1, , Dongyu Li1, , Shujuan Chen1, , Chengjie Li1, , Haiyu Guan1, , Dongsheng Wang2, , Xiaoli Nie1, ,

  • 1 Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China
  • 2 Institute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha 410008, China

Received: June 30, 2023       Accepted: January 22, 2024       Published: March 14, 2024
How to Cite

Copyright: © 2024 Yao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


High-sucrose diets are common in daily life but harmful to human health. Cyclocarya paliurus leaves (CPL) are a kind of tea used to alleviate metabolic diseases and are widely used in China. However, the effects of CPL on high-sucrose-induced obesity are unknown. This study aimed to describe the changes in gut metabolism induced by a high-sucrose diet and to reveal the potential mechanisms through which CPL alleviate high-sucrose diet-induced obesity. A high-sucrose-induced obesity model was generated in C57BL/6J and KM mice. The effects of CPL on obese mice were evaluated, and changes in the gut microbiota and intestinal metabolites induced by CPL treatment were observed. Furthermore, the fecal microbiota transplantation (FMT) method was used to prove that the effects of CPL on high-sucrose induced obesity depend on the changes of gut microbiota. The results of the C57BL/6J mouse experiment revealed that high-sucrose intake induced fat deposition and altered the gut microbiota. CPL treatment decreased fat deposition and alleviated disorders of the gut microbiota. Furthermore, CPL treatment increased the utilization of amnio acids, long fatty acids and saccharides and produced more bile acids, indole derivatives and less trimethylamine (TMA). A confirmatory experiment in KM mice also revealed that CPL can alleviate obesity, ameliorate intestinal metabolic disorders, and upregulate the expression of tight junction proteins in the intestinal mucosa. These results demonstrated that CPL could prevent high sucrose-induced obesity and generate more beneficial intestinal microbial metabolites but less harmful intestinal microbial metabolites.


AUC: Area under curve; β-HDCA: Beta-Hyodeoxycholic acid; β-MCA: Beta-Muricholic acid; β-UDCA: Beta-Ursodeoxycholic acid; CA: Cholic acid; CCPP: Cyclocarya paliurus polysaccharides; CDCA: Chenodeoxycholic acid; CPL: Cyclocarya paliurus leaves; CRE: Creatinine; DCA: Deoxycholic acid; FBG: Fast blood glucose; FMT: Fecal microbiota transplantation; HCA: Hyocholic acid; HDCA: Hyodeoxycholic acid; HDL-C: High-density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment of insulin resistance; IsoDCA: Isolithocholic acid; IsoLCA: Isolithocholic acid; LCA: Lithocholic acid; LDL-C: Low-density lipoprotein cholesterol; MDCA: Murideoxycholic acid; NEG: Negative; OGTT: Oral glucose tolerance test; OTU: Operational taxonomic unit; PBAs: Primary bile acids; PCA: Principal component analysis; POS: Positive; SBAs: Secondary bile acids; SCFAs: Short fatty acids; TC: Total cholesterol; T2DM: Type 2 diabetic mellitus; TG: Triglyceride; TMA: Trimethylamine; TMAO: Trimethylamine N-oxide; UA: Uric acid; UCA: Ursodeoxycholic acid; UDCA: Ursodeoxycholic acid; 3-DHCA: 3-Dehydrocholic acid; 7-DHCA: 7-Dehydrocholic acid; 7-KLCA: 7-Ketolithocholic acid.